23:29 , May 3, 2019 |  BioCentury  |  Product Development

Independents’ day: after their first solo launch, biotechs look to new partnering strategies

Having taken their first products to market alone, the new class of independent biotechs face decisions for what to keep and what to change as they seek to build sustainable value as end-to-end companies. One...
02:24 , Mar 29, 2019 |  BC Innovations  |  Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
20:03 , Feb 11, 2019 |  BC Extra  |  Company News

Agios' Schenkein joins GV

Less than two weeks after stepping down as CEO of Agios Pharmaceuticals Inc. (NASDAQ:AGIO), David Schenkein has joined GV as general partner. Schenkein, who will remain executive chairman of Agios, will co-lead the firm’s life...
20:51 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

FDA issues safety warning for Agios, Celgene's Idhifa

FDA issued a warning to healthcare professionals and patients that signs or symptoms of differentiation syndrome, a life-threatening side effect of acute myelogenous leukemia drug Idhifa enasidenib, are not being recognized in some patients receiving...
19:06 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

MMRF launches MyDRUG multiple myeloma platform trial

The Multiple Myeloma Research Foundation launched the collaborative MyDRUG platform trial to identify new treatment options for molecularly defined subgroups of patients. The Phase I/II signal-finding study builds upon the patient group's 2011 CoMMpass trial,...
18:25 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

FDA approves two drugs for first-line AML

FDA approved on Nov. 28 two drugs for first-line treatment of acute myelogenous leukemia, setting off a race in a setting that's been void of new approvals for patients who do not harbor an FMS-like...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
15:49 , Nov 29, 2018 |  BC Extra  |  Clinical News

MMRF launches MyDRUG multiple myeloma platform trial

The Multiple Myeloma Research Foundation launched the collaborative MyDRUG platform trial to identify new treatment options for molecularly defined subgroups of patients. The Phase I/II signal-finding study builds upon the patient group's 2011 CoMMpass trial,...
20:40 , Nov 21, 2018 |  BC Extra  |  Company News

FDA approves two drugs for first-line AML

FDA approved on Wednesday two drugs for first-line treatment of acute myelogenous leukemia, setting off a race in a setting that's been void of new approvals for patients who do not harbor an FMS-like tyrosine...
00:07 , Sep 5, 2018 |  BC Extra  |  Company News

Management tracks: Agios, Radius

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said David Schenkein will step down as CEO and become executive chairman, effective Feb. 1, 2019. He will succeed Chairman John Maraganore, who is also CEO at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)....